Cardiovascular Complications of Novel Multiple Myeloma Treatments
Weijuan Li1, R Frank Cornell1, Daniel Lenihan1
1From Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, New York, NY(W.L.); Division of Hematology and Oncology, Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, TN(R.F.C., M.J., J.M.), Cardiovascular Division(D.L., D.S., J.M.) and Cardio-Oncology Program(D.L., D.S., J.M.), Vanderbilt University School of Medicine, Nashville, TN; and Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA(G.P.).
No abstract available in PubMed .
More Related Videos
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
Related Concept Videos
Cardiomyopathy VI: Nursing Management
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy II: Dilated Cardiomyopathy
Chronic Kidney Disease II: Clinical Manifestations
Hemodialysis II: Procedure and Complications
Myocarditis III: Medical Management
